Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 32.23 Billion KRW | -25.05% |
| 2022 | 43 Billion KRW | 121.39% |
| 2021 | 19.42 Billion KRW | -19.39% |
| 2020 | 24.09 Billion KRW | -31.36% |
| 2019 | 35.1 Billion KRW | 14.19% |
| 2018 | 30.74 Billion KRW | 21.55% |
| 2017 | 25.29 Billion KRW | -13.22% |
| 2016 | 29.14 Billion KRW | 26.26% |
| 2015 | 23.08 Billion KRW | 29.65% |
| 2014 | 17.8 Billion KRW | 14.55% |
| 2013 | 15.54 Billion KRW | 15.16% |
| 2012 | 13.49 Billion KRW | 6.56% |
| 2011 | 12.66 Billion KRW | -36.89% |
| 2010 | 20.06 Billion KRW | 42.74% |
| 2009 | 14.06 Billion KRW | 21.62% |
| 2008 | 11.56 Billion KRW | 21.07% |
| 2007 | 9.54 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 15.36 Billion KRW | 138.15% |
| 2024 Q2 | -2.08 Billion KRW | -108.82% |
| 2023 Q3 | 6.74 Billion KRW | -32.98% |
| 2023 Q2 | 10.06 Billion KRW | 12.04% |
| 2023 Q1 | 8.97 Billion KRW | 108.36% |
| 2023 FY | 32.23 Billion KRW | -25.05% |
| 2023 Q4 | 6.45 Billion KRW | -4.33% |
| 2022 Q1 | 13.92 Billion KRW | 29.94% |
| 2022 FY | 43 Billion KRW | 121.39% |
| 2022 Q2 | 10.19 Billion KRW | -26.77% |
| 2022 Q3 | 14.58 Billion KRW | 43.05% |
| 2022 Q4 | 4.3 Billion KRW | -70.45% |
| 2021 FY | 19.42 Billion KRW | -19.39% |
| 2021 Q1 | -2.27 Billion KRW | -245.06% |
| 2021 Q2 | 4.48 Billion KRW | 297.4% |
| 2021 Q4 | 10.71 Billion KRW | 64.81% |
| 2021 Q3 | 6.5 Billion KRW | 45.03% |
| 2020 Q1 | 10.07 Billion KRW | -2.66% |
| 2020 Q4 | 1.56 Billion KRW | -68.95% |
| 2020 Q3 | 5.04 Billion KRW | -31.99% |
| 2020 FY | 24.09 Billion KRW | -31.36% |
| 2020 Q2 | 7.41 Billion KRW | -26.44% |
| 2019 Q3 | 8.39 Billion KRW | -0.69% |
| 2019 FY | 35.1 Billion KRW | 14.19% |
| 2019 Q2 | 8.44 Billion KRW | 6.77% |
| 2019 Q4 | 10.35 Billion KRW | 23.39% |
| 2019 Q1 | 7.91 Billion KRW | 9.98% |
| 2018 Q3 | 7.12 Billion KRW | -6.17% |
| 2018 FY | 30.74 Billion KRW | 21.55% |
| 2018 Q1 | 8.82 Billion KRW | 107.09% |
| 2018 Q4 | 7.19 Billion KRW | 0.96% |
| 2018 Q2 | 7.59 Billion KRW | -13.94% |
| 2017 Q1 | 4.78 Billion KRW | -45.23% |
| 2017 Q4 | 4.26 Billion KRW | -51.07% |
| 2017 FY | 25.29 Billion KRW | -13.22% |
| 2017 Q3 | 8.71 Billion KRW | 15.52% |
| 2017 Q2 | 7.54 Billion KRW | 57.73% |
| 2016 FY | 29.14 Billion KRW | 26.26% |
| 2016 Q2 | 6.98 Billion KRW | 37.71% |
| 2016 Q1 | 5.06 Billion KRW | -42.64% |
| 2016 Q3 | 8.36 Billion KRW | 19.87% |
| 2016 Q4 | 8.72 Billion KRW | 4.3% |
| 2015 FY | 23.08 Billion KRW | 29.65% |
| 2015 Q1 | 4.21 Billion KRW | -21.19% |
| 2015 Q4 | 8.83 Billion KRW | 110.84% |
| 2015 Q3 | 4.19 Billion KRW | -28.28% |
| 2015 Q2 | 5.84 Billion KRW | 38.8% |
| 2014 Q2 | 4.03 Billion KRW | 40.94% |
| 2014 Q1 | 2.86 Billion KRW | -41.56% |
| 2014 FY | 17.8 Billion KRW | 14.55% |
| 2014 Q4 | 5.34 Billion KRW | -3.93% |
| 2014 Q3 | 5.56 Billion KRW | 37.78% |
| 2013 Q2 | 4.76 Billion KRW | 110.73% |
| 2013 Q3 | 3.62 Billion KRW | -23.98% |
| 2013 Q4 | 4.9 Billion KRW | 35.37% |
| 2013 FY | 15.54 Billion KRW | 15.16% |
| 2013 Q1 | 2.26 Billion KRW | -54.89% |
| 2012 Q3 | 2.95 Billion KRW | -7.55% |
| 2012 Q4 | 5.01 Billion KRW | 69.52% |
| 2012 FY | 13.49 Billion KRW | 6.56% |
| 2012 Q1 | 2.05 Billion KRW | 0.0% |
| 2012 Q2 | 3.19 Billion KRW | 55.63% |
| 2011 Q1 | 5.13 Billion KRW | 85.31% |
| 2011 Q2 | 4.53 Billion KRW | -11.71% |
| 2011 Q3 | 3.23 Billion KRW | -28.66% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 12.66 Billion KRW | -36.89% |
| 2010 Q2 | 5.84 Billion KRW | 12.6% |
| 2010 Q1 | 5.19 Billion KRW | 78.71% |
| 2010 FY | 20.06 Billion KRW | 42.74% |
| 2010 Q3 | 6.24 Billion KRW | 6.75% |
| 2010 Q4 | 2.77 Billion KRW | -55.55% |
| 2009 Q4 | 2.9 Billion KRW | -44.2% |
| 2009 FY | 14.06 Billion KRW | 21.62% |
| 2009 Q3 | 5.2 Billion KRW | 45.37% |
| 2009 Q2 | 3.58 Billion KRW | 56.14% |
| 2009 Q1 | 2.29 Billion KRW | -34.74% |
| 2008 Q3 | 2.22 Billion KRW | -22.47% |
| 2008 Q2 | 2.86 Billion KRW | -2.78% |
| 2008 Q1 | 2.95 Billion KRW | 87.85% |
| 2008 FY | 11.56 Billion KRW | 21.07% |
| 2008 Q4 | 3.51 Billion KRW | 57.97% |
| 2007 FY | 9.54 Billion KRW | 0.0% |
| 2007 Q4 | 1.57 Billion KRW | -32.49% |
| 2007 Q3 | 2.32 Billion KRW | -16.49% |
| 2007 Q2 | 2.78 Billion KRW | -2.67% |
| 2007 Q1 | 2.86 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8742.117% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 58.075% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 140.513% |
| HANDOK Inc. | 12.57 Billion KRW | -156.246% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1720.437% |
| Yuhan Corporation | 74.56 Billion KRW | 56.771% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -188.347% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 278.649% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 85.667% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -954.718% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -124.612% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -5304.535% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -3244.465% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -19.242% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8742.117% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 515.582% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -699.102% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 146.08% |
| JW Holdings Corporation | 143.66 Billion KRW | 77.564% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 160.341% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 86.929% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.865% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 168.013% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -365.326% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -398.109% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -269.16% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8742.117% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 33.905% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 75.839% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.865% |
| Yuhan Corporation | 74.56 Billion KRW | 56.771% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -54.075% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -933.966% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 25.031% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.865% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -57.353% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 41.341% |
| CKD Bio Corp. | -20.15 Billion KRW | 259.944% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -27.392% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 0.899% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 168.013% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 2.758% |
| Boryung Corporation | 68.26 Billion KRW | 52.784% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 185.962% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -124.612% |
| JW Lifescience Corporation | 32.09 Billion KRW | -0.44% |